ECSP13011139A - Anticuerpos contra la angiopoyetina 2 humana - Google Patents

Anticuerpos contra la angiopoyetina 2 humana

Info

Publication number
ECSP13011139A
ECSP13011139A ECSP13011139A ECSP13011139A EC SP13011139 A ECSP13011139 A EC SP13011139A EC SP13011139 A ECSP13011139 A EC SP13011139A EC SP13011139 A ECSP13011139 A EC SP13011139A
Authority
EC
Ecuador
Prior art keywords
antibodies against
angiopoyetine
human
antibodies
ang
Prior art date
Application number
Other languages
English (en)
Inventor
Joerg Regula
Werner Scheuer
Christian Klein
Ulrich Brinkmann
Remko Albert Griep
Anita Kavlie
Klaus Kaluza
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40585738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13011139(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP13011139A publication Critical patent/ECSP13011139A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere a anticuerpos contra la angiopoyetina 2 humana (anticuerpos anti-ANG-2), a métodos para su obtención, a composiciones farmacéuticas que contienen dichos anticuerpos y a usos de los mismos.
ECSP13011139 2008-12-16 2013-10-25 Anticuerpos contra la angiopoyetina 2 humana ECSP13011139A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08021835 2008-12-16

Publications (1)

Publication Number Publication Date
ECSP13011139A true ECSP13011139A (es) 2014-10-31

Family

ID=40585738

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2011011139A ECSP11011139A (es) 2008-12-16 2011-06-16 Anticuerpos contra la angiopoyetina 2 humana
ECSP13011139 ECSP13011139A (es) 2008-12-16 2013-10-25 Anticuerpos contra la angiopoyetina 2 humana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EC2011011139A ECSP11011139A (es) 2008-12-16 2011-06-16 Anticuerpos contra la angiopoyetina 2 humana

Country Status (34)

Country Link
US (12) US8133979B2 (es)
EP (1) EP2379592B1 (es)
JP (2) JP5559191B2 (es)
KR (2) KR101445518B1 (es)
CN (3) CN103739709B (es)
AR (2) AR074756A1 (es)
AU (1) AU2009328613B2 (es)
BR (2) BR122013022089B1 (es)
CA (2) CA2916481C (es)
CL (2) CL2011001285A1 (es)
CR (2) CR20110321A (es)
CY (1) CY1116264T1 (es)
DK (1) DK2379592T3 (es)
EC (2) ECSP11011139A (es)
ES (1) ES2534635T3 (es)
HK (2) HK1172349A1 (es)
HR (1) HRP20150439T1 (es)
HU (1) HUE024545T2 (es)
IL (2) IL213039A (es)
MA (1) MA32876B1 (es)
MX (1) MX2011005908A (es)
MY (2) MY155654A (es)
NZ (2) NZ600005A (es)
PE (2) PE20140814A1 (es)
PH (1) PH12013502192A1 (es)
PL (1) PL2379592T3 (es)
PT (1) PT2379592E (es)
RU (2) RU2569461C2 (es)
SG (1) SG172216A1 (es)
SI (1) SI2379592T1 (es)
TW (2) TWI482631B (es)
UA (2) UA103912C2 (es)
WO (1) WO2010069532A1 (es)
ZA (2) ZA201103990B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
AU2008346734A1 (en) 2008-01-03 2009-07-16 The Scripps Research Institute Antibody targeting through a modular recognition domain
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
RU2015153109A (ru) 2009-09-16 2019-01-15 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применения
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CN102221615A (zh) * 2011-03-31 2011-10-19 广州华灿医药科技有限公司 一种基于Angiogenin检测的双抗夹心ELISA方法
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2012137993A1 (en) * 2011-04-05 2012-10-11 Neopharm Co., Ltd. Antibodies against angiopoietins 1 and 2, and their use
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
EP3628329B1 (en) 2011-09-30 2022-08-10 Dana-Farber Cancer Institute, Inc. Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
KR20140127854A (ko) 2012-02-10 2014-11-04 제넨테크, 인크. 단일-쇄 항체 및 다른 이종다량체
MX2014014162A (es) * 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
WO2014001324A1 (en) 2012-06-27 2014-01-03 Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
RU2015100656A (ru) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
HUE056217T2 (hu) 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
KR101967345B1 (ko) 2012-10-18 2019-04-09 삼성전자주식회사 안지오포이에틴-2와 인테그린 간의 결합을 저해하는 펩타이드 및 그 용도
WO2014108854A1 (en) * 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
AU2014236867A1 (en) 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
KR102131371B1 (ko) 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 특이적 항체 및 그의 용도
US9828422B2 (en) 2013-07-29 2017-11-28 Samsung Electronics Co., Ltd. Anti-Ang2 antibody
KR102146845B1 (ko) 2013-07-30 2020-08-21 삼성전자주식회사 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
KR102196450B1 (ko) 2013-09-17 2020-12-30 삼성전자주식회사 Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제
MX2016008099A (es) * 2013-12-20 2016-10-13 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40.
KR102206029B1 (ko) 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
EP3925973A1 (en) 2014-03-14 2021-12-22 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
US9957333B2 (en) * 2014-04-17 2018-05-01 Case Western Reserve University Anti-CEP antibody or fragment thereof
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
US9994632B2 (en) 2014-05-26 2018-06-12 Samsung Electronics Co., Ltd. Humanized or affinity-matured anti Ang-2 antibody and uses thereof
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016061551A1 (en) * 2014-10-17 2016-04-21 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
KR20170082594A (ko) * 2014-11-10 2017-07-14 에프. 호프만-라 로슈 아게 항-ang2 항체 및 사용 방법
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
KR20170105609A (ko) 2015-01-28 2017-09-19 피어이스 파마슈티컬즈 게엠베하 신생혈관형성에 특이적인 신규한 단백질
WO2016161410A2 (en) 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
WO2017030909A1 (en) 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
WO2017053807A2 (en) 2015-09-23 2017-03-30 Genentech, Inc. Optimized variants of anti-vegf antibodies
SG10201911499TA (en) 2015-11-30 2020-01-30 Pieris Australia Pty Ltd Novel anti-angiogenic fusion polypeptides
WO2018114728A1 (en) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
KR102143132B1 (ko) * 2016-12-26 2020-08-10 기초과학연구원 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
MX2019011141A (es) 2017-03-22 2019-11-05 Genentech Inc Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares.
SG10202107829YA (en) 2017-03-22 2021-08-30 Genentech Inc Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
WO2019164219A1 (en) * 2018-02-20 2019-08-29 Institute For Basic Science Anti-angiopoietin-2 antibodies and uses thereof
KR102497171B1 (ko) 2018-02-20 2023-02-08 기초과학연구원 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
CN113728004A (zh) * 2019-02-25 2021-11-30 药物抗体公司 抗Ang2抗体及其用途
TW202115112A (zh) * 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
WO2021183849A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CA3169967A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
CN115734971A (zh) * 2020-06-22 2023-03-03 信达生物制药(苏州)有限公司 抗ang-2抗体及其用途
IL302089A (en) 2020-10-15 2023-06-01 Hoffmann La Roche Non-covalent protein-hyaluronan conjugates for long-term ocular delivery

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
RU2277411C1 (ru) * 2004-12-15 2006-06-10 Ольга Алексеевна Кост Фармацевтическая композиция для лечения глазных болезней, связанных с нарушением микроциркуляции и/или воспалительными процессами
AU2005319382B2 (en) 2004-12-21 2011-04-07 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
CA2799802A1 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
WO2007014073A2 (en) * 2005-07-22 2007-02-01 Amgen Inc. Concentrated protein lyophilates, methods, and uses
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007068895A1 (en) 2005-12-15 2007-06-21 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EA017417B1 (ru) * 2006-02-01 2012-12-28 Сефалон Астралия Пти Лтд. КОНСТРУКТ ОДНОДОМЕННОГО АНТИТЕЛА, КОТОРЫЙ СВЯЗЫВАЕТСЯ С ЧЕЛОВЕЧЕСКИМ TNF-α, И ЕГО ПРИМЕНЕНИЕ
RU2509085C2 (ru) * 2008-01-28 2014-03-10 Медиммун Лимитед Стабилизированные антитела против ангиопоэтина-2 и их применение
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
HUE056217T2 (hu) * 2012-07-13 2022-02-28 Roche Glycart Ag Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében

Also Published As

Publication number Publication date
US20150284457A1 (en) 2015-10-08
AU2009328613B2 (en) 2013-09-05
JP5559191B2 (ja) 2014-07-23
PH12013502192B1 (en) 2015-10-12
PT2379592E (pt) 2015-03-24
US20170029493A1 (en) 2017-02-02
US20120141500A1 (en) 2012-06-07
ES2534635T3 (es) 2015-04-27
TW201322996A (zh) 2013-06-16
CN102746400B (zh) 2015-12-16
HRP20150439T1 (hr) 2015-05-22
ZA201307297B (en) 2019-07-31
TWI482631B (zh) 2015-05-01
KR101445518B1 (ko) 2014-10-01
US20210388071A1 (en) 2021-12-16
SG172216A1 (en) 2011-07-28
IL213039A (en) 2015-03-31
CA2916481A1 (en) 2010-06-24
SI2379592T1 (sl) 2015-06-30
ZA201103990B (en) 2016-01-27
WO2010069532A1 (en) 2010-06-24
CA2916481C (en) 2018-05-15
ECSP11011139A (es) 2011-07-29
UA105151C2 (uk) 2014-04-10
AU2009328613A1 (en) 2010-06-24
CR20110321A (es) 2011-07-14
NZ592856A (en) 2012-06-29
US20200262904A1 (en) 2020-08-20
KR20110084536A (ko) 2011-07-25
US8133979B2 (en) 2012-03-13
JP5814317B2 (ja) 2015-11-17
HK1172349A1 (zh) 2013-04-19
US20180282404A1 (en) 2018-10-04
PE20120551A1 (es) 2012-05-21
RU2569107C2 (ru) 2015-11-20
AR092487A2 (es) 2015-04-22
CR20130418A (es) 2013-10-04
MA32876B1 (fr) 2011-12-01
US9073986B2 (en) 2015-07-07
RU2569461C2 (ru) 2015-11-27
KR101381012B1 (ko) 2014-04-11
CN103739709B (zh) 2016-08-24
NZ600005A (en) 2012-08-31
TWI396549B (zh) 2013-05-21
UA103912C2 (uk) 2013-12-10
TW201026328A (en) 2010-07-16
AR074756A1 (es) 2011-02-09
US20100159587A1 (en) 2010-06-24
US20230227543A1 (en) 2023-07-20
HUE024545T2 (hu) 2016-01-28
IL226350A (en) 2016-10-31
HK1195775A1 (zh) 2014-11-21
RU2011129204A (ru) 2013-01-27
JP2012511897A (ja) 2012-05-31
CN102257008A (zh) 2011-11-23
PL2379592T3 (pl) 2015-07-31
MX2011005908A (es) 2011-06-20
CY1116264T1 (el) 2017-02-08
EP2379592B1 (en) 2015-02-11
IL226350A0 (en) 2013-06-27
CL2011001285A1 (es) 2011-09-16
JP2014000089A (ja) 2014-01-09
BRPI0923434A2 (pt) 2017-09-19
CN103739709A (zh) 2014-04-23
EP2379592A1 (en) 2011-10-26
US20130156789A1 (en) 2013-06-20
PH12013502192A1 (en) 2015-10-12
US9109027B2 (en) 2015-08-18
BR122013022089B1 (pt) 2021-10-13
CA2744624C (en) 2018-01-02
KR20130103822A (ko) 2013-09-24
WO2010069532A8 (en) 2012-05-10
BR122013022089A2 (pt) 2019-05-28
US8399626B2 (en) 2013-03-19
US8361747B2 (en) 2013-01-29
US20140065707A1 (en) 2014-03-06
US20120142091A1 (en) 2012-06-07
CA2744624A1 (en) 2010-06-24
MY158438A (en) 2016-10-14
DK2379592T3 (en) 2015-03-02
CN102746400A (zh) 2012-10-24
IL213039A0 (en) 2011-07-31
RU2013140625A (ru) 2015-03-10
CL2012003054A1 (es) 2012-12-14
US9340609B2 (en) 2016-05-17
PE20140814A1 (es) 2014-07-10
MY155654A (en) 2015-11-13
US20140065151A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
CR20110466A (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
CR20110166A (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2
ECSP10010295A (es) Formulacion de anticuerpo
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
ECSP12011701A (es) Anticuerpos anti-cdcp1 humanizados
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
ECSP12011995A (es) Anticuerpos anti-her3 y usos de los mismos
CR20140431A (es) Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
CR11731A (es) Composiciones y procedimientos para su preparación y uso
ECSP088632A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
ECSP11010822A (es) 4-fenil-1h-pirazoles insecticidas
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ECSP099561A (es) Formulación de nevirapina de liberación prolongada
UY33208A (es) Composiciones que comprenden productos de azúcar cisteína
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
BRPI0800596A2 (pt) método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.
CO6390001A2 (es) Anticuerpos contra la angiopoyetina 2 humana
BRPI0908780A2 (pt) Composto, composição para o clareamento da pele, e, métodos para o clareamento da pele e para a preparação de um composto de éster
GT201200066A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen